Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Pharmacoeconomics|December 19, 2019
A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data MaturityTim S Grant, Darren Burns, Christopher Kiff, et al.
Pharmacoeconomics - Open|December 17, 2020
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in EnglandBen Rothwell, Christopher Kiff, Caroline Ling, et al.
Clinicoeconomics and Outcomes Research : CEOR|May 24, 2019
The impact of increased post-progression survival on the cost-effectiveness of interventions in oncologyJenny Retzler, Heather Davies, Michelle Jenks, et al.
Drug Discovery Today|June 23, 2019
Early Access to Medicines Scheme: real-world data collectionHok Pang, Meng Wang, Christopher Kiff, et al.
Future Oncology (London, England)|June 8, 2021
Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK Early Access to Medicines SchemeMira Soni, Christopher Kiff, Robert Carroll, et al.
Pharmacoeconomics|January 11, 2021
What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell CarcinomaSven L Klijn, Elisabeth Fenwick, Sonja Kroep, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 29, 2021
A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 DimensionsJames W Shaw, Bryan Bennett, Andrew Trigg, et al.
Pageof 1